MET and cancer: In present study, we reported that IFITM3 served as a novel modulator of HGF/MET-mediated AKT signaling that suppressed FOXO3 (Forkhead Box O3), consequently leading to c-MYC (MYC proto-oncogene) mediated cancer proliferation, migration, stemness and drug resistance.